Acquired Resistance to Immune Checkpoint Inhibitors.
Reads0
Chats0
TLDR
The barriers to progress and emerging clinical reports interrogating acquired resistance are examined with the goal to facilitate efforts to overcome acquired resistance to ICIs in the future.About:
This article is published in Cancer Cell.The article was published on 2020-04-13 and is currently open access. It has received 348 citations till now.read more
Citations
More filters
Journal Article
Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma
David Liu,Bastian Schilling,Derek Liu,Antje Sucker,Elisabeth Livingstone,Livnat Jerby-Amon,Lisa Zimmer,Ralf Gutzmer,Imke Satzger,Carmen Loquai,Stephan Grabbe,Natalie I. Vokes,Claire A. Margolis,Jake Conway,Meng Xiao He,Haitham Elmarakeby,Felix Dietlein,Diana Miao,Adam Tracy,Helen Gogas,Simone M. Goldinger,Jochen Utikal,Christian U. Blank,Ricarda Rauschenberg,Dagmar von Bubnoff,Angela M. Krackhardt,Benjamin Weide,Sebastian Haferkamp,Felix Kiecker,Ben Izar,Levi A. Garraway,Aviv Regev,Keith T. Flaherty,Annette Paschen,Eliezer M. Van Allen,Dirk Schadendorf +35 more
TL;DR: Analysis of fully clinically annotated and sequenced melanoma tumor samples collected before anti-PD1 treatment suggests that determinants of response differ on the basis of previous anti-CTLA4 therapy, and that tumor mutational burden may not be a strong predictor of response across melanoma subtypes.
Journal ArticleDOI
Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up
Yves Fradet,Joaquim Bellmunt,David J. Vaughn,J.-L. Lee,Lawrence Fong,N. J. Vogelzang,Miguel Angel Climent,Daniel P. Petrylak,Toni K. Choueiri,Andrea Necchi,Winald R. Gerritsen,Howard Gurney,David I. Quinn,Stéphane Culine,Cora N. Sternberg,Kijoeng Nam,Tara L. Frenkl,Rodolfo F. Perini,R. de Wit,Dean F. Bajorin +19 more
TL;DR: Long-term results (>2 years’ follow-up) were consistent with those of previously reported analyses, demonstrating continued clinical benefit of pembrolizumab over chemotherapy for efficacy and safety for treatment of locally advanced/metastatic, platinum-refractory UC.
Journal ArticleDOI
Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis.
Scott J. Antonia,Hossein Borghaei,Suresh S. Ramalingam,Leora Horn,Javier de Castro Carpeño,Adam Pluzanski,Marco Angelo Burgio,Marina Chiara Garassino,Laura Q.M. Chow,Scott N. Gettinger,Lucio Crinò,David Planchard,Charles Butts,Alexander Drilon,Joanna Wojcik-Tomaszewska,Gregory A. Otterson,Shruti Agrawal,Ang Li,John R. Penrod,Julie R. Brahmer +19 more
TL;DR: Patients with advanced NSCLC treated with nivolumab achieved a greater duration of response compared with patients treated with docetaxel, which was associated with a long-term survival advantage.
Journal ArticleDOI
CD8+ T cell differentiation and dysfunction in cancer
Mary Philip,Andrea Schietinger +1 more
TL;DR: In this paper, a review of CD8+ T cell differentiation to dysfunctional states during tumorigenesis is presented, highlighting similarities and differences between T cell dysfunction and other hyporesponsive T cell states and discuss the spatio-temporal factors contributing to T cell state heterogeneity in tumours.
Journal ArticleDOI
Pyroptosis: a new paradigm of cell death for fighting against cancer.
Yixin Tan,Quanzhu Chen,Quanzhu Chen,Xiaoling Li,Xiaoling Li,Zhaoyang Zeng,Zhaoyang Zeng,Wei Xiong,Wei Xiong,Guiyuan Li,Guiyuan Li,Xiayu Li,Jianbo Yang,Bo Xiang,Bo Xiang,Mei Yi,Mei Yi +16 more
TL;DR: In this article, the regulatory mechanisms of pyroptosis and the tumor suppressive function were discussed and the potential application in cancer immune therapy was also discussed, where the authors discussed the attribution of pyroposis in reprogramming tumor microenvironments and restoration of anti-tumor immunity.
References
More filters
Journal ArticleDOI
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
Suzanne L. Topalian,F. Stephen Hodi,Julie R. Brahmer,Scott N. Gettinger,David Smith,David F. McDermott,John D. Powderly,Richard D. Carvajal,Jeffrey A. Sosman,Michael B. Atkins,Philip D. Leming,David R. Spigel,Scott J. Antonia,Leora Horn,Charles G. Drake,Drew M. Pardoll,Lieping Chen,William H. Sharfman,Robert A. Anders,Janis M. Taube,Tracee L. McMiller,Haiying Xu,Alan J. Korman,Maria Jure-Kunkel,Shruti Agrawal,Dan McDonald,Georgia Kollia,Ashok Kumar Gupta,Jon M. Wigginton,Mario Sznol +29 more
TL;DR: Anti-PD-1 antibody produced objective responses in approximately one in four to one in five patients with non-small-cell lung cancer, melanoma, or renal-cell cancer; the adverse-event profile does not appear to preclude its use.
Journal ArticleDOI
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
Martin Reck,Delvys Rodriguez-Abreu,Andrew G. Robinson,Rina Hui,Tibor Csőszi,Andrea Fülöp,Maya Gottfried,Nir Peled,Ali Tafreshi,Sinead Cuffe,Mary O'Brien,Suman Rao,Katsuyuki Hotta,Melanie A. Leiby,Gregory M. Lubiniecki,Yue Shentu,Reshma A. Rangwala,Julie R. Brahmer +17 more
TL;DR: Pembrolizumab is a humanized monoclonal antibody against programmed death 1 (PD-1) that has antitumor activity in advanced non-small-cell lung cancer (NSCLC), with increased activity in tumors that express PD-L1 as mentioned in this paper.
Journal ArticleDOI
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Naiyer A. Rizvi,Naiyer A. Rizvi,Matthew D. Hellmann,Matthew D. Hellmann,Alexandra Snyder,Alexandra Snyder,Pia Kvistborg,Vladimir Makarov,Jonathan J. Havel,William Lee,Jianda Yuan,Phillip Wong,Teresa S. Ho,Martin L. Miller,Natasha Rekhtman,Andre L. Moreira,Fawzia Ibrahim,Cameron Bruggeman,Billel Gasmi,Roberta Zappasodi,Yuka Maeda,Chris Sander,Edward B. Garon,Taha Merghoub,Jedd D. Wolchok,Jedd D. Wolchok,Ton N. Schumacher,Timothy A. Chan,Timothy A. Chan +28 more
TL;DR: Treatment efficacy was associated with a higher number of mutations in the tumors, and a tumor-specific T cell response paralleled tumor regression in one patient, suggesting that the genomic landscape of lung cancers shapes response to anti–PD-1 therapy.
Journal ArticleDOI
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Paul C. Tumeh,Christina L. Harview,Jennifer H. Yearley,I. Peter Shintaku,Emma Taylor,Lidia Robert,Bartosz Chmielowski,Marko Spasic,Gina Henry,Voicu Ciobanu,Alisha N. West,Manuel Carmona,Christine Kivork,Elizabeth Seja,Grace Cherry,Antonio Gutierrez,Tristan Grogan,Christine Mateus,Gorana Tomasic,John A. Glaspy,Ryan O. Emerson,Harlan Robins,Robert H. Pierce,David Elashoff,Caroline Robert,Antoni Ribas +25 more
TL;DR: It is shown that pre-existing CD8+ T cells distinctly located at the invasive tumour margin are associated with expression of the PD-1/PD-L1 immune inhibitory axis and may predict response to therapy.
Journal ArticleDOI
Pembrolizumab for the treatment of non-small cell lung cancer
Edward B. Garon,Naiyer A. Rizvi,Rina Hui,Natasha B. Leighl,Ani Sarkis Balmanoukian,Joseph Paul Eder,Amita Patnaik,Charu Aggarwal,Matthew A. Gubens,Leora Horn,Enric Carcereny,Myung-Ju Ahn,Enriqueta Felip,Jong-Seok Lee,Matthew D. Hellmann,Omid Hamid,Jonathan W. Goldman,Jean-Charles Soria,Marisa Dolled-Filhart,Ruth Z. Rutledge,Jin Zhang,Jared Lunceford,Reshma A. Rangwala,Gregory M. Lubiniecki,Charlotte Roach,Kenneth Emancipator,Leena Gandhi +26 more
TL;DR: Pembrolizumab had an acceptable side-effect profile and showed antitumor activity in patients with advanced non-small-cell lung cancer and PD-L1 expression in at least 50% of tumor cells correlated with improved efficacy of pembrolIZumab.
Related Papers (5)
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Naiyer A. Rizvi,Naiyer A. Rizvi,Matthew D. Hellmann,Matthew D. Hellmann,Alexandra Snyder,Alexandra Snyder,Pia Kvistborg,Vladimir Makarov,Jonathan J. Havel,William Lee,Jianda Yuan,Phillip Wong,Teresa S. Ho,Martin L. Miller,Natasha Rekhtman,Andre L. Moreira,Fawzia Ibrahim,Cameron Bruggeman,Billel Gasmi,Roberta Zappasodi,Yuka Maeda,Chris Sander,Edward B. Garon,Taha Merghoub,Jedd D. Wolchok,Jedd D. Wolchok,Ton N. Schumacher,Timothy A. Chan,Timothy A. Chan +28 more
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy.
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Paul C. Tumeh,Christina L. Harview,Jennifer H. Yearley,I. Peter Shintaku,Emma Taylor,Lidia Robert,Bartosz Chmielowski,Marko Spasic,Gina Henry,Voicu Ciobanu,Alisha N. West,Manuel Carmona,Christine Kivork,Elizabeth Seja,Grace Cherry,Antonio Gutierrez,Tristan Grogan,Christine Mateus,Gorana Tomasic,John A. Glaspy,Ryan O. Emerson,Harlan Robins,Robert H. Pierce,David Elashoff,Caroline Robert,Antoni Ribas +25 more
Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer
Julie R. Brahmer,Karen L. Reckamp,Paul Baas,Lucio Crinò,Wilfried Eberhardt,Elena Poddubskaya,Scott J. Antonia,Adam Pluzanski,Everett E. Vokes,Esther Holgado,David M. Waterhouse,Neal Ready,Justin F. Gainor,Osvaldo Arén Frontera,Libor Havel,Martin Steins,Marina Chiara Garassino,Joachim G.J.V. Aerts,Manuel Domine,Luis Paz-Ares,Martin Reck,Christine Baudelet,Christopher T. Harbison,Brian Lestini,David R. Spigel +24 more